Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer / 南方医科大学学报
Journal of Southern Medical University
;
(12): 446-449, 2015.
Article
Dans Chinois
| WPRIM
| ID: wpr-239159
ABSTRACT
<p><b>OBJECTIVE</b>To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.</p><p><b>METHODS</b>Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). The progression-free survival, objective response rate and disease control rate were evaluated to compare the efficacy of gefitinib and erlotinib.</p><p><b>RESULTS</b>There were no significant differences in the objective response rate (P=0.711) and disease control rate (P=0.861) between the two groups. The progression-free survival of gefitinib group and erlotinib group was 8.0 months and 10.0 months, respectively. The efficacy of the two drugs was similar (P=0.293).</p><p><b>CONCLUSION</b>There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.</p>
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Quinazolines
/
Carcinome pulmonaire non à petites cellules
/
Survie sans rechute
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Récepteurs ErbB
/
Chlorhydrate d'erlotinib
/
Tumeurs du poumon
/
Métabolisme
/
Mutation
Limites du sujet:
Humains
langue:
Chinois
Texte intégral:
Journal of Southern Medical University
Année:
2015
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS